Can the Japanese phase I study be waived?

By Yoshiaki Hattori and Masami Tamura2024-03-06T15:00:00

Prior to the introduction of new guidance, before including Japanese participants into a multi-regional clinical trial (MRCT), the sponsor needed to conduct a standalone Japanese phase I study to ensure no significant difference in safety/pharmacokinetics (PK) between Japanese and non-Japanese participants. This requirement has been considered an obstacle for non-Japanese companies to conduct MRCTs including Japanese participants, which can lead to drug lag* and drug loss* in Japan. Based on this, the Ministry of Health, Labour and Welfare (MHLW)† took this situation seriously and reviewed the requirement for standalone Japanese Phase I trials.

How to read this journal article

Thank you for visiting Regulatory Rapporteur. Journal articles are restricted to registered users and TOPRA members.

Already a member or have an account? Sign in.

1. REGISTER FOR FREE

Free access to selected content

Register now to continue to access industry news, editorials and podcasts plus one member-only journal article each month.

Create your own library to save your favourite content.

Create a free account

2. Members login

Already a TOPRA member?

Log-in now using your MyTOPRA credentials, for unlimited access to all Regulatory Rapporteur journal articles, the online archive and latest industry news and podcasts.

3. JOIN TOPRA

Special offer on TOPRA membership

Join TOPRA today and get membership until the end of 2025 for the exclusive rate of £230.

In addition to unlimited access to Regulatory Rapporteur content, as a TOPRA member you will also be able to enjoy a wide range of benefits including career-boosting resources, savings on our events and training, and access to our regional networks and special interest groups.

This offer ends on 30 September 2024.

Become a member